University of Pittsburgh and accelerator BioMotiv are set to generate a spinout based on anti-inflammatory research by Rama Mallampalli and Beibei Chen.

University of Pittsburgh is partnering Biomotiv, a drug development accelerator backed by family-run commercialisation vehicle Harrington Project for Discovery & Development, to form a US-based biotech spinout, Koutif Therapeutics.

Koutif will aim to tackle inflammatory diseases with techniques based on research by Rama Mallampalli, chief of pulmonary, allergy and crucial care at University of Pittsburgh Medical Centre, and Beibei Chen, director of the university’s Small Molecule Therapeutic Centre.

The pair hope to use their compound discovery, BC-1261, to obstruct pathways…